news
RELY-ABLE®: Unprecedented long-term data support safety profile and sustained efficacy of Pradaxa®
8 November 2012 | By Boehringer Ingelheim
Pivotal data from the RELY-ABLE® study have provided additional data...
List view / Grid view
Stroke
news
Cost effectiveness and clinical efficacy of Pradaxa® (dabigatran etexilate) versus rivaroxaban analysed
24 August 2012 | By Boehringer Ingelheim
Indirect comparison based on the RE-LY® trial and the Rocket AF trial suggests advantages of Pradaxa® in stroke prevention in patients with atrial fibrillation...
news
First study to evaluate alternative to warfarin for mechanical heart valve patients launched with Pradaxa® (dabigatran etexilate)
20 June 2012 | By Boehringer Ingelheim
The design of the RE-ALIGN study published...
news
AF patients who require surgery benefit from a shorter treatment interruption on dabigatran etexilate (Pradaxa®) compared to warfarin
18 June 2012 | By Boehringer Ingelheim
Pradaxa® is associated with a substantially shorter interruption of oral anticoagulation therapy...
news
FDA affirms superiority of Pradaxa® (dabigatran etexilate) 150mg over warfarin in reduction of both ischaemic and haemorrhagic strokes
6 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has updated the US prescribing information for Pradaxa®...
news
Pradaxa® (dabigatran etexilate) receives final NICE recommendation for stroke prevention in atrial fibrillation in the UK
19 March 2012 | By NICE
Pradaxa® must now be made available for use by the UK National Health Service (NHS)...
news
Bayer’s Xarelto® approved in the EU for the prevention of stroke in patients
20 December 2011 | By Bayer HealthCare
The only new oral anticoagulant approved in three indications across all 27 EU member states...
news
Pradaxa® (dabigatran etexilate, 150mg bid) shows significant reduction in the risk of stroke
New data from two RE-LY® trial subgroup analyses show that dabigatran etexilate 150mg bid consistently reduces the risk of stroke in atrial fibrillation (AF) compared to well-controlled warfarin, irrespective of whether patients use antiplatelet [1] or other concomitant therapies, such as the anti-arrhythmics amiodarone or verapamil. [2] The relative benefits…
news
ELIQUIS® (apixaban) superior to Warfarin for the reduction of stroke or systemic embolism
28 August 2011 | By Bristol-Myers Squibb Company, Pfizer
Significantly less major bleeding in patients with Atrial Fibrillation in Phase 3 ARISTOTLE trial...
news
Apixaban statistically superior to aspirin in reducing the composite of stroke or systemic embolism
10 February 2011 | By Pfizer
Bristol-Myers Squibb Company and Pfizer Inc. announce the publication of their AVERROES study of apixaban in The New England Journal of Medicine...
